TY - JOUR
T1 - Mining Disaggregase Sequence Space to Safely Counter TDP-43, FUS, and α-Synuclein Proteotoxicity
AU - Tariq, Amber
AU - Lin, Jia Bei
AU - Jackrel, Meredith E.
AU - Hesketh, Christina D.
AU - Carman, Peter J.
AU - Mack, Korrie L.
AU - Weitzman, Rachel
AU - Gambogi, Craig
AU - Hernandez Murillo, Oscar A.
AU - Sweeny, Elizabeth A.
AU - Gurpinar, Esin
AU - Yokom, Adam L.
AU - Gates, Stephanie N.
AU - Yee, Keolamau
AU - Sudesh, Saurabh
AU - Stillman, Jacob
AU - Rizo, Alexandra N.
AU - Southworth, Daniel R.
AU - Shorter, James
N1 - Publisher Copyright:
© 2019 The Author(s)
PY - 2019/8/20
Y1 - 2019/8/20
N2 - Hsp104 is an AAA+ protein disaggregase, which can be potentiated via diverse mutations in its autoregulatory middle domain (MD) to mitigate toxic misfolding of TDP-43, FUS, and α-synuclein implicated in fatal neurodegenerative disorders. Problematically, potentiated MD variants can exhibit off-target toxicity. Here, we mine disaggregase sequence space to safely enhance Hsp104 activity via single mutations in nucleotide-binding domain 1 (NBD1) or NBD2. Like MD variants, NBD variants counter TDP-43, FUS, and α-synuclein toxicity and exhibit elevated ATPase and disaggregase activity. Unlike MD variants, non-toxic NBD1 and NBD2 variants emerge that rescue TDP-43, FUS, and α-synuclein toxicity. Potentiating substitutions alter NBD1 residues that contact ATP, ATP-binding residues, or the MD. Mutating the NBD2 protomer interface can also safely ameliorate Hsp104. Thus, we disambiguate allosteric regulation of Hsp104 by several tunable structural contacts, which can be engineered to spawn enhanced therapeutic disaggregases with minimal off-target toxicity.
AB - Hsp104 is an AAA+ protein disaggregase, which can be potentiated via diverse mutations in its autoregulatory middle domain (MD) to mitigate toxic misfolding of TDP-43, FUS, and α-synuclein implicated in fatal neurodegenerative disorders. Problematically, potentiated MD variants can exhibit off-target toxicity. Here, we mine disaggregase sequence space to safely enhance Hsp104 activity via single mutations in nucleotide-binding domain 1 (NBD1) or NBD2. Like MD variants, NBD variants counter TDP-43, FUS, and α-synuclein toxicity and exhibit elevated ATPase and disaggregase activity. Unlike MD variants, non-toxic NBD1 and NBD2 variants emerge that rescue TDP-43, FUS, and α-synuclein toxicity. Potentiating substitutions alter NBD1 residues that contact ATP, ATP-binding residues, or the MD. Mutating the NBD2 protomer interface can also safely ameliorate Hsp104. Thus, we disambiguate allosteric regulation of Hsp104 by several tunable structural contacts, which can be engineered to spawn enhanced therapeutic disaggregases with minimal off-target toxicity.
UR - http://www.scopus.com/inward/record.url?scp=85070688471&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070688471&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2019.07.069
DO - 10.1016/j.celrep.2019.07.069
M3 - Article
C2 - 31433984
AN - SCOPUS:85070688471
SN - 2211-1247
VL - 28
SP - 2080-2095.e6
JO - Cell Reports
JF - Cell Reports
IS - 8
ER -